Cerexa

Cerexa was a privately held biopharmaceutical company founded in the mid-2000s (its cerexa.com domain was registered in March 2005) to develop anti-infective therapies for serious, drug-resistant bacterial infections in the hospital setting. Its lead program was ceftaroline fosamil, a fifth-generation cephalosporin antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA), in-licensed from Takeda Pharmaceutical Company and carried forward by Forest Laboratories; the compound was approved by the FDA on October 29, 2010 and marketed as Teflaro in the United States and Zinforo in Europe. Cerexa was backed by venture investors including Canaan Partners, and its programs ultimately passed through Forest Laboratories into the Actavis/Allergan combination (Forest Laboratories was acquired by Actavis on July 1, 2014) and on to AbbVie. Cerexa no longer operates as an independent company and has no developer surface: it publishes no API, no SDKs, no GitHub organization and no documentation, and its historical cerexa.com domain is now registered and operated by AbbVie, 301-redirecting to AbbVie's Allergan page. This profile is retained as a historical company record in the API Evangelist network.

Cerexa is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Anti-Infectives, and Antibiotics.

🌐 Visit website 📡 Source on GitHub

7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsAnti-InfectivesAntibioticsLife SciencesHealthcareAcquired

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 7.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/cerexa: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Source (apis.yml)

aid: cerexa
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/cerexa.png
name: Cerexa
description: 'Cerexa was a privately held biopharmaceutical company founded in the mid-2000s (its cerexa.com domain was registered
  in March 2005) to develop anti-infective therapies for serious, drug-resistant bacterial infections in the hospital setting.
  Its lead program was ceftaroline fosamil, a fifth-generation cephalosporin antibiotic active against methicillin-resistant
  Staphylococcus aureus (MRSA), in-licensed from Takeda Pharmaceutical Company and carried forward by Forest Laboratories;
  the compound was approved by the FDA on October 29, 2010 and marketed as Teflaro in the United States and Zinforo in Europe.
  Cerexa was backed by venture investors including Canaan Partners, and its programs ultimately passed through Forest Laboratories
  into the Actavis/Allergan combination (Forest Laboratories was acquired by Actavis on July 1, 2014) and on to AbbVie. Cerexa
  no longer operates as an independent company and has no developer surface: it publishes no API, no SDKs, no GitHub organization
  and no documentation, and its historical cerexa.com domain is now registered and operated by AbbVie, 301-redirecting to
  AbbVie''s Allergan page. This profile is retained as a historical company record in the API Evangelist network.'
url: https://raw.githubusercontent.com/api-evangelist/cerexa/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-status-detail: No independent operations and no API surface. Programs passed through Forest Laboratories into Actavis/Allergan
  and are now held by AbbVie, which also controls the legacy cerexa.com domain.
x-successor: abbvie
x-legacy-domain: cerexa.com
x-legacy-domain-redirects-to: https://www.abbvie.com/allergan.html
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Anti-Infectives
- Antibiotics
- Life Sciences
- Healthcare
- Acquired
apis: []
common:
- type: DomainSecurity
  url: security/cerexa-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 2
  pass: local-v1

Cerexa

Kin Score

Security Posture 1

Cerexa Domain Security

Resources

Access & Security 1

Source (apis.yml)